{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:01:33Z","timestamp":1790323293323,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002224","name":"Melanoma Research Foundation","doi-asserted-by":"publisher","award":["1287389"],"award-info":[{"award-number":["1287389"]}],"id":[{"id":"10.13039\/100002224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30 CA288142-01A"],"award-info":[{"award-number":["F30 CA288142-01A"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA2630001"],"award-info":[{"award-number":["U54 CA2630001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Melanoma SPORE grant NCI P50 CA225450"],"award-info":[{"award-number":["Melanoma SPORE grant NCI P50 CA225450"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA2630001"],"award-info":[{"award-number":["U54 CA2630001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02781-9","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:43:59Z","timestamp":1789609439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genotype-driven tumor ecosystems drive immune evasion and immunotherapy resistance in melanoma"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8841-7393","authenticated-orcid":false,"given":"Milad","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8039-565X","authenticated-orcid":false,"given":"Irineu","family":"Illa-Bochaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3827-5694","authenticated-orcid":false,"given":"Tara","family":"Muijlwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6420-2934","authenticated-orcid":false,"given":"Ines","family":"Delclaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7675-7355","authenticated-orcid":false,"given":"Katherine S.","family":"Ventre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-8966","authenticated-orcid":false,"given":"George","family":"Jour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8167-0307","authenticated-orcid":false,"given":"Paola Angulo","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agrima","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-9983","authenticated-orcid":false,"given":"Amanda W.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1472-1971","authenticated-orcid":false,"given":"Iman","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-2121","authenticated-orcid":false,"given":"Markus","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"4","key":"2781_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"6382","key":"2781_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"20","key":"2781_CR3","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015;373(20):1926\u201336.","journal-title":"N Engl J Med"},{"issue":"2","key":"2781_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ccell.2025.01.009","volume":"43","author":"J Schiantarelli","year":"2025","unstructured":"Schiantarelli J, Benamar M, Park J, Sax HE, Oliveira G, Bosma-Moody A, et al. Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. Cancer Cell. 2025;43(2):308\u2013. \u2013\u200916.e6.","journal-title":"Cancer Cell"},{"issue":"7688","key":"2781_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature25187","volume":"553","author":"Z Eroglu","year":"2018","unstructured":"Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018;553(7688):347\u201350.","journal-title":"Nature"},{"issue":"23","key":"2781_CR6","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMra2034861","volume":"384","author":"BD Curti","year":"2021","unstructured":"Curti BD, Faries MB. Recent Advances in the Treatment of Melanoma. N Engl J Med. 2021;384(23):2229\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"2781_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","volume":"11","author":"A Tasdogan","year":"2025","unstructured":"Tasdogan A, Sullivan RJ, Katalinic A, Lebbe C, Whitaker D, Puig S, et al. Cutaneous melanoma. Nat Reviews Disease Primers. 2025;11(1):23.","journal-title":"Nat Reviews Disease Primers"},{"issue":"3","key":"2781_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jid.2022.07.022","volume":"143","author":"G Jour","year":"2023","unstructured":"Jour G, Illa-Bochaca I, Ibrahim M, Donnelly D, Zhu K, Miera EV, et al. Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment. J Invest Dermatol. 2023;143(3):444\u2013. \u2013\u200955.e8.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2781_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/1878-0261.12050","volume":"11","author":"H Cirenajwis","year":"2017","unstructured":"Cirenajwis H, Lauss M, Ekedahl H, Torngren T, Kvist A, Saal LH, et al. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol. 2017;11(4):438\u201351.","journal-title":"Mol Oncol"},{"issue":"17","key":"2781_CR10","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1158\/0008-5472.CAN-24-3904","volume":"85","author":"M Ibrahim","year":"2025","unstructured":"Ibrahim M, Illa-Bochaca I, Jour G, Vega-Saenz de Miera E, Fracasso J, Ruggles K, et al. NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma. Cancer Res. 2025;85(17):3348\u201364.","journal-title":"Cancer Res"},{"issue":"8","key":"2781_CR11","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","volume":"74","author":"MH Nissan","year":"2014","unstructured":"Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014;74(8):2340\u201350.","journal-title":"Cancer Res"},{"issue":"3","key":"2781_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","volume":"3","author":"O Maertens","year":"2013","unstructured":"Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013;3(3):338\u201349.","journal-title":"Cancer Discov"},{"issue":"7","key":"2781_CR13","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas N","year":"2015","unstructured":"Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161(7):1681\u201396.","journal-title":"Cell"},{"key":"2781_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2021.09.035","volume":"159","author":"CM Thielmann","year":"2021","unstructured":"Thielmann CM, Chorti E, Matull J, Murali R, Zaremba A, Lodde G, et al. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. Eur J Cancer. 2021;159:113\u201324.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2781_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42(2):293\u2013304.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2781_CR16","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16(12):1289\u201396.","journal-title":"Nat Methods"},{"key":"2781_CR17","unstructured":"Kassambara A. ggpubr:\u2018ggplot2\u2019based publication ready plots. R package version. 2018:2. https:\/\/cir.nii.ac.jp\/crid\/1370869855128041364."},{"key":"2781_CR18","doi-asserted-by":"publisher","first-page":"e1929","DOI":"10.7717\/peerj-cs.1929","volume":"10","author":"X Chen","year":"2024","unstructured":"Chen X, G\u00fcttel S. Fast and exact fixed-radius neighbor search based on sorting. PeerJ Comput Sci. 2024;10:e1929.","journal-title":"PeerJ Comput Sci"},{"issue":"1","key":"2781_CR19","first-page":"100","volume":"28","author":"JA Hartigan","year":"2018","unstructured":"Hartigan JA, Wong MA. A K-Means Clustering Algorithm. J Royal Stat Soc Ser C: Appl Stat. 2018;28(1):100\u20138.","journal-title":"J Royal Stat Soc Ser C: Appl Stat"},{"issue":"1","key":"2781_CR20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12(1):1088.","journal-title":"Nat Commun"},{"key":"2781_CR21","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2016. ISBN 978-3-319-24277-4."},{"issue":"4","key":"2781_CR22","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et al. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. Cell Rep. 2017;20(4):854\u201367.","journal-title":"Cell Rep"},{"key":"2781_CR23","doi-asserted-by":"crossref","unstructured":"Ibrahim M, Illa-Bochaca I, Fa\u2019ak F, Monson KR, Ferguson R, Lyu C, Vega-Saenz de Miera, Johannet P, Chou M, Mastroianni J, Darvishian F, Kirchhoff T, Zhong J, Krogsgaard M, & Osman I. Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes. Cancers. 2024;16(1):18. https:\/\/www.mdpi.com\/2072-6694\/16\/1\/18.","DOI":"10.3390\/cancers16010018"},{"issue":"1","key":"2781_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/cancers16010018","volume":"16","author":"M Ibrahim","year":"2024","unstructured":"Ibrahim M, Illa-Bochaca I, Fa\u2019ak F, Monson KR, Ferguson R, Lyu C, et al. Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes. Cancers. 2024;16(1):18.","journal-title":"Cancers"},{"issue":"5","key":"2781_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018;33(5):890\u2013e9045.","journal-title":"Cancer Cell"},{"key":"2781_CR26","doi-asserted-by":"crossref","unstructured":"van der Maten M, Reijnen C, Pijnenborg JMA, & Zegers MM. L1 Cell Adhesion Molecule in Cancer, a Systematic Review on Domain-Specific Functions. International Journal of Molecular Sciences. 2019;20(17):4180. https:\/\/www.mdpi.com\/1422-0067\/20\/17\/4180.","DOI":"10.3390\/ijms20174180"},{"key":"2781_CR27","doi-asserted-by":"publisher","first-page":"1602452","DOI":"10.3389\/fonc.2025.1602452","volume":"15","author":"W Hou","year":"2025","unstructured":"Hou W. Role of TGF\u03b2-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy. Front Oncol. 2025;15:1602452.","journal-title":"Front Oncol"},{"issue":"15","key":"2781_CR28","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1158\/0008-5472.CAN-17-3876","volume":"78","author":"V Quaranta","year":"2018","unstructured":"Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, et al. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Res. 2018;78(15):4253\u201369.","journal-title":"Cancer Res"},{"key":"2781_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","volume":"457","author":"R Saleh","year":"2019","unstructured":"Saleh R, Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019;457:168\u201379.","journal-title":"Cancer Lett"},{"issue":"5","key":"2781_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"6282","key":"2781_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189\u201396.","journal-title":"Science"},{"issue":"7","key":"2781_CR32","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. 2024;42(7):1202\u2013e168.","journal-title":"Cancer Cell"},{"key":"2781_CR33","doi-asserted-by":"publisher","unstructured":"Hazini A, Fisher K, & Seymour L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer. 2021;9(8). https:\/\/doi.org\/10.1136\/jitc-2021-002899.","DOI":"10.1136\/jitc-2021-002899"},{"key":"2781_CR34","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3389\/fimmu.2019.01806","volume":"10","author":"RS Accolla","year":"2019","unstructured":"Accolla RS, Ramia E, Tedeschi A, Forlani G, CIITA-Driven MHC. Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine. Front Immunol. 2019;10:1806.","journal-title":"Front Immunol"},{"key":"2781_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.molimm.2021.12.013","volume":"142","author":"I Mantel","year":"2022","unstructured":"Mantel I, Sadiq BA, Blander JM. Spotlight on TAP and its vital role in antigen presentation and cross-presentation. Mol Immunol. 2022;142:105\u201319.","journal-title":"Mol Immunol"},{"key":"2781_CR36","doi-asserted-by":"publisher","unstructured":"Hsieh CH, Jian CZ, Lin LI, Low GS, Ou PY, Hsu C, & Ou DL. Potential Role of CXCL13\/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. Cancers (Basel). 2022;14(2). https:\/\/doi.org\/10.3390\/cancers14020294.","DOI":"10.3390\/cancers14020294"},{"issue":"10","key":"2781_CR37","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41416-022-01763-0","volume":"126","author":"S Seitz","year":"2022","unstructured":"Seitz S, Dreyer TF, Stange C, Steiger K, Br\u00e4uer R, Scheutz L, et al. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. Br J Cancer. 2022;126(10):1470\u201380.","journal-title":"Br J Cancer"},{"issue":"1","key":"2781_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pro.3978","volume":"30","author":"R Oughtred","year":"2021","unstructured":"Oughtred R, Rust J, Chang C, Breitkreutz BJ, Stark C, Willems A, et al. The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 2021;30(1):187\u2013200.","journal-title":"Protein Sci"},{"issue":"2","key":"2781_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrm3048","volume":"12","author":"R Avraham","year":"2011","unstructured":"Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011;12(2):104\u201317.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"22","key":"2781_CR40","doi-asserted-by":"publisher","first-page":"31892","DOI":"10.18632\/oncotarget.7441","volume":"7","author":"Z Li","year":"2016","unstructured":"Li Z, Yang Z, Passaniti A, Lapidus RG, Liu X, Cullen KJ, et al. A positive feedback loop involving EGFR\/Akt\/mTORC1 and IKK\/NF-kB regulates head and neck squamous cell carcinoma proliferation. Oncotarget. 2016;7(22):31892\u2013906.","journal-title":"Oncotarget"},{"key":"2781_CR41","doi-asserted-by":"publisher","unstructured":"Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun. 2015;6:6051. https:\/\/doi.org\/10.1038\/ncomms7051.","DOI":"10.1038\/ncomms7051"},{"issue":"2","key":"2781_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342\u201350.","journal-title":"J Pharmacol Exp Ther"},{"key":"2781_CR43","doi-asserted-by":"publisher","unstructured":"Bauman Y, Drayman N, Ben-Nun-Shaul O, Vitenstein A, Yamin R, Ophir Y, et al. Downregulation of the stress-induced ligand ULBP1 following SV40 infection confers viral evasion from NK cell cytotoxicity. Oncotarget. 2016;7(13):15369\u201315381. https:\/\/doi.org\/10.18632\/oncotarget.8085.","DOI":"10.18632\/oncotarget.8085"},{"issue":"3","key":"2781_CR44","doi-asserted-by":"publisher","first-page":"115365","DOI":"10.1016\/j.celrep.2025.115365","volume":"44","author":"D Berry","year":"2025","unstructured":"Berry D, Moldoveanu D, Rajkumar S, Lajoie M, Lin T, Tchelougou D, et al. The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma. Cell Rep. 2025;44(3):115365.","journal-title":"Cell Rep"},{"issue":"3","key":"2781_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"key":"2781_CR46","doi-asserted-by":"publisher","first-page":"175883592094941","DOI":"10.1177\/1758835920949418","volume":"13","author":"M Fasano","year":"2021","unstructured":"Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, et al. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol. 2021;13:1758835920949418.","journal-title":"Ther Adv Med Oncol"},{"key":"2781_CR47","doi-asserted-by":"publisher","unstructured":"Santaniello A, Napolitano F, Servetto A, De Placido P, Silvestris N, Bianco C, et al. Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers (Basel). 2019;11(10):1419. https:\/\/doi.org\/10.3390\/cancers11101419.","DOI":"10.3390\/cancers11101419"},{"issue":"50","key":"2781_CR48","doi-asserted-by":"publisher","first-page":"eabn7983","DOI":"10.1126\/sciadv.abn7983","volume":"8","author":"X Wang","year":"2022","unstructured":"Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, et al. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Sci Adv. 2022;8(50):eabn7983.","journal-title":"Sci Adv"},{"issue":"62","key":"2781_CR49","doi-asserted-by":"publisher","first-page":"106132","DOI":"10.18632\/oncotarget.22190","volume":"8","author":"A Passarelli","year":"2017","unstructured":"Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017;8(62):106132\u201342.","journal-title":"Oncotarget"},{"issue":"4","key":"2781_CR50","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/CJI.0b013e31821b724a","volume":"34","author":"H Kim","year":"2011","unstructured":"Kim H, Kim SH, Kim MJ, Kim SJ, Park SJ, Chung JS, et al. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother. 2011;34(4):372\u201381.","journal-title":"J Immunother"},{"issue":"6","key":"2781_CR51","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","volume":"22","author":"AG Sacco","year":"2021","unstructured":"Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883\u201392.","journal-title":"Lancet Oncol"},{"key":"2781_CR52","doi-asserted-by":"publisher","first-page":"e2200421","DOI":"10.1200\/PO.22.00421","volume":"7","author":"KB Wisinski","year":"2023","unstructured":"Wisinski KB, Flamand Y, Wilson MA, Luke JJ, Tawbi HA, Hong F, et al. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO Precis Oncol. 2023;7:e2200421.","journal-title":"JCO Precis Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02781-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02781-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02781-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:23:01Z","timestamp":1790320981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02781-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2781"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02781-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All protocols were approved by NYU Institutional Review Board at NYU Langone Health (IRB #10362) and were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from participants to allow using their specimens for research and to conduct follow-up.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this manuscript does not contain any individual-level data requiring consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"227"}}